Skip to main content
. Author manuscript; available in PMC: 2017 Jul 31.
Published in final edited form as: JAMA Cardiol. 2016 May 1;1(2):163–171. doi: 10.1001/jamacardio.2016.0008

Figure 3. Left Ventricular (LV) Pressure Development (+dP/dt), LV Decline (−dP/dt), and Symptom Scores.

Figure 3

A, LV peak −dP/dt decreased (LV pressure decline more rapid) in D4 + 5 participants (n = 22) compared with placebo participants (n = 14) 4 weeks after treatment. This between-group difference was statistically significant (P < .03). B, There was no between-group difference in LV peak +dP/dt between 14 placebo and 21 D4 + 5 participants (P = .42). C, D4 + 5 participants (baseline, n = 22; 4 weeks, n = 23; 12 weeks, n = 22) had reduced symptoms 12 weeks after randomization (P = .0005); no significant changes were noted in the placebo group (baseline, n = 13; 4 weeks, n = 14; 12 weeks, n = 13) (P = .16). Error bars denote SE. There was no between-group difference in symptom scores between D4 + 5 and placebo at 4 weeks (P = .85) and 12 weeks (P = .24). AC6 indicates adenylyl cyclase 6.